Understanding Antiphospholipid Syndrome: A Comprehensive Guide

Antiphospholipid Syndrome (APS) is an autoimmune disorder characterized by the presence of antiphospholipid antibodies in the blood, which can lead to blood clots in arteries and veins, as well as pregnancy-related complications. This article aims to provide a comprehensive overview of APS, drawing upon recent research and clinical insights, including data from the European Alliance of Associations for Rheumatology and information from institutions like UCLA Health.

What is Antiphospholipid Syndrome?

Antiphospholipid syndrome (APS) is an autoimmune condition where the body's immune system mistakenly attacks normal proteins in the blood. This can lead to the formation of blood clots, increasing the risk of various health issues, including recurrent pregnancy loss, stroke, and deep vein thrombosis.

Cardiovascular Risk in Antiphospholipid Syndrome

The European Alliance of Associations for Rheumatology recommendations for cardiovascular risk management highlighted the importance of traditional cardiovascular risk factor control in antiphospholipid syndrome (APS). A cross-sectional study collected cardiovascular risk factor data from medical records of patients in 17 centers from 11 countries between Jan 1, 2015, and Jan 1, 2020 (extended to 2022 for some centers unable to complete the survey by the end of 2020 due to the COVID-19 pandemic). The study included 1003 patients with APS, with a median age of 47 years and a median disease duration of 11 years. Of these, 54% had primary APS and 46% had SLE-related APS.

Prevalence of Cardiovascular Risk Factors

The study revealed a high prevalence of cardiovascular risk factors among APS patients:

Hypertension: 41%
Hyperlipidemia: 34%
Obesity: 32%
Current Smoking: 19%

Inadequate control of individual cardiovascular risk factors, such as blood pressure, BMI, and lipids, was also noted across the patient population.

Read also: Aspiring Healers' Fears

Primary APS vs. SLE-Related APS

Significant differences were observed between primary APS and SLE-related APS:

SLE-related APS showed a higher prevalence of hypertension (50% vs. 33%) and hyperlipidemia (40% vs. 30%).
Primary APS had a higher prevalence of current smoking (22% vs. 16%).

Patients with primary APS also exhibited worse target attainment for smoking cessation and blood pressure control compared to those with SLE-related APS.

UCLA Lupus Program and Comprehensive Care

The UCLA Lupus Program is a comprehensive, multidisciplinary team of experts dedicated to meeting the specific needs of patients with Systemic Lupus Erythematosus. Lupus can affect many different organs in the body. Treatment options include medications to suppress the immune system and reduce inflammation. In addition to caring for patients, their providers conduct clinical trials to evaluate potential new treatments for lupus. Their Lupus Center is dedicated to identifying and addressing racial, ethnic and socioeconomic disparities in lupus care and outcomes. The UCLA Lupus Program team is made up of specialists from different fields of medicine who work together to provide comprehensive care to patients with lupus. As lupus can affect different parts of the body, this multidisciplinary approach allows them to craft individual treatment plans for each patient. The UCLA Lupus Program only evaluates adult patients (those 18 years and older).

Recurrent Pregnancy Loss and APS

Recurrent pregnancy loss, defined as two or more pregnancy losses, can be emotionally and physically challenging for couples. While most pregnancy losses result from chromosomal abnormalities, a woman’s immune system and blood clotting factors may also play a role. Antiphospholipid antibodies, particularly anticardiolipin antibody and lupus anticoagulant, will likely be checked. These antibodies are related to the antiphospholipid syndrome, which may be related to pregnancy loss. Any woman with a pregnancy loss at or beyond the 10th week of gestation (with a “normal” appearing fetus) or with three recurrent losses at any gestational age should be screened, according to the American College of Obstetrics and Gynecology (ACOG).

Causes of Recurrent Pregnancy Loss

Several factors can contribute to recurrent pregnancy loss:

Read also: Scholarships and Grants

Chromosomal Abnormalities: These are the most common cause of miscarriages.
Uterine Abnormalities: Irregularly shaped uterus or issues with blood supply.
Immune System Abnormalities: Including antiphospholipid syndrome.
Hormone Abnormalities: Such as thyroid disease and diabetes.
Blood Clotting Abnormalities: Which may affect pregnancy loss.

Testing for Recurrent Pregnancy Loss

A physician will take a detailed medical, surgical, family, and genetic history and perform a physical examination. Testing that may be done includes karyotype analysis of both partners. The karyotype is the chromosomal, or genetic, make-up of a person. The purpose is to find abnormalities in the parents that could be passed on to the offspring, resulting in miscarriage. Because karyotype abnormalities are relatively rare, a doctor may choose to not perform this test unless other, more common, abnormalities are ruled out.

The uterus (the womb) and the uterine cavity (inside of the womb) will often be evaluated. There are several ways to evaluate the uterine cavity, including an ultrasound, saline ultrasound, hysterosalpingogram X-ray, MRI (magnetic resonance imaging), and/or hysteroscopy (to look inside the uterus). An ultrasound is often done as a first test. The ultrasound can give information about the shape of the uterus and the presence of fibroids (benign round muscle tumors). A saline ultrasound is when fluid is injected into the inside of the uterus so that the physician can see if there are abnormalities with the inside of the uterus, including polyps (growths of the lining of the uterus), fibroids, or scarring. A hysterosalpingogram is an X-ray of the uterus and tubes, and can help a doctor to evaluate not only the inside of the uterus, but also the tubes (whether they are open or not). A hysteroscopy is a minor surgical procedure where a camera is placed through the cervix into the uterus so that the doctor can directly visualize the inside of the uterus. The doctor can also remove polyps and fibroids and can resect a septum or scar tissue, if present. A uterine septum is an abnormality of the shape of the uterus that a woman has since birth. An MRI may be done to evaluate the location of fibroids and in cases of abnormalities of the shape of a uterus.

Antiphospholipid antibodies, particularly anticardiolipin antibody and lupus anticoagulant, will likely be checked. These antibodies are related to the antiphospholipid syndrome, which may be related to pregnancy loss. Any woman with a pregnancy loss at or beyond the 10th week of gestation (with a “normal” appearing fetus) or with three recurrent losses at any gestational age should be screened, according to the American College of Obstetrics and Gynecology (ACOG). Testing for inherited thrombophilias, or abnormally increased blood clotting, is not routinely recommended in women who have experienced recurrent fetal loss because studies have not shown a benefit of giving medicine to prevent clots in these patients. However, testing for abnormal blood clotting should be done if there is a personal history of blood clots associated with risk factors such as surgery, bone fractures, or prolonged immobilization, or if a patient has a parent or sibling with a disorder of excessive blood clotting.

Tests of hormone function may also be done. Thyroid function tests and thyroid antibodies may be checked, along with measurement of prolactin, the hormone responsible for breast milk production. Ovarian reserve tests may be performed, which indicate how well an ovary is functioning. Some studies indicate that poorer ovarian function, as shown by these hormone tests, may be related to chromosomal abnormalities of the eggs in the ovary. Testing for diabetes may be done if a woman is at risk for or has manifestations of diabetes.

Treatment for Recurrent Pregnancy Loss

The treatment recommendations for patients with recurrent pregnancy loss are based on the underlying cause of recurrent pregnancy loss. No matter what the results of the work-up are, the chance for a successful future pregnancy is high: 77% if the work-up showed no abnormalities, and 71% if an abnormality was found.

Individuals in whom a karyotypic (a chromosomal or genetic) abnormality is found are often referred for genetic counseling. There, a specialist can discuss what the genetic abnormality is and the likelihood of having a chromosomally normal or abnormal pregnancy in the future. Some affected couples may choose to undergo prenatal genetic studies during pregnancy to check the genetic make-up of the offspring with either 1) chorionic villus sampling (CVS), in which a piece of placenta is biopsied late in the first trimester or early in the second trimester, or 2) amniocentesis, which removes some of the amniotic fluid (the fluid that surrounds the baby during pregnancy) for analysis. In vitro fertilization (IVF) with preimplantation genetic diagnosis (PGD) can also be done. With this process, the woman takes shots for several days so that many eggs grow in her ovaries. The eggs are then retrieved from the ovaries in a minor surgical procedure. One sperm is then injected into each egg and the embryo is allowed to grow. One cell of the embryo is then biopsied and the genetic make-up is analyzed to avoid the transfer of an affected embryo.

If a uterine abnormality is found, surgery may be performed depending on the defect. If antiphospolipid syndrome is diagnosed, certain medications that reduce blood clot formation may be given. If thyroid dysfunction or diabetes are diagnosed, specific medications can be prescribed.

Over 50% of patients with recurrent pregnancy loss will have unexplained recurrent pregnancy loss, which means that no specific cause could be identified in the work-up. Various treatments may be offered to these patients, but there is no universal recommendation for treatment of these patients.

Clinical Trials and Research

RAY121 in Immunological Diseases (RAINBOW Trial) open to eligible people ages 18-85 This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose administration in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) and immune thrombocytopenia (ITP). at UC Irvine

Management and Treatment

Management of APS typically involves a combination of lifestyle modifications and medical interventions. Key strategies include:

Anticoagulation: Medications like warfarin or heparin are used to prevent blood clot formation.
Cardiovascular Risk Factor Management: Addressing hypertension, hyperlipidemia, obesity, and smoking is crucial.
Immunosuppression: In some cases, medications that suppress the immune system may be necessary.

tags: #antiphospholipid #syndrome #ucla #health